Alyeska Investment Group L.P. Sells 414,148 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Alyeska Investment Group cut its Arrowhead Pharmaceuticals stake by 87.6%, selling 414,148 shares and retaining 58,722 shares valued at approximately $4.8 million. Institutional investors collectively own 62.61% of ARWR.
• Arrowhead reported positive 12-month Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran, which reduced acute pancreatitis episodes in patients with severe hypertriglyceridemia. Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $98.42.
• ARWR shares opened at $82.74, while the company reported stronger-than-expected quarterly revenue of $75.25 million but missed on earnings, posting a loss of $1.36 per share versus the $1.23 expected loss.

Alyeska Investment Group L.P. cut its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 87.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,722 shares of the biotechnology company's stock after selling 414,148 shares during the period. Alyeska Investment Group L.P.'s holdings in Arrowhead Pharmaceuticals were worth $4,786,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Carolina Wealth Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company's stock worth $28,000 after buying an additional 154 shares during the last quarter. First Horizon Corp lifted its position in shares of Arrowhead Pharmaceuticals by 36.2% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company's stock valued at $41,000 after buying an additional 174 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 1.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company's stock valued at $737,000 after purchasing an additional 178 shares during the last quarter. Optiver Holding B.V. raised its position in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 186 shares during the period. Finally, Versant Capital Management Inc raised its position in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 248 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Phase 3 SHASTA-3 and SHASTA-4 results indicated that plozasiran reduced acute pancreatitis episodes in patients with severe hypertriglyceridemia. The 12-month data strengthen the investment case for the program and could improve confidence in its commercial potential. Arrowhead Pharmaceuticals presents Phase 3 SHASTA-3 and SHASTA-4 data
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $120 price target, implying roughly 45% potential upside from the referenced share price.
• Positive Sentiment: Chardan Capital also reaffirmed its “buy” rating, with a $115 target representing approximately 39% upside, while RBC maintained an “outperform” rating and a $100 target, or about 21% upside. The cluster of bullish targets signals continued Wall Street confidence in ARWR’s pipeline. Analysts are bullish on Arrowhead Pharmaceuticals and BioNTech
• Neutral Sentiment: The company’s discussion of 12-month SHASTA-3 and SHASTA-4 results provides additional clinical detail, but the transcript itself does not represent a new regulatory approval or commercial launch. Arrowhead discusses SHASTA-3 and SHASTA-4 12-month results

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 11,600 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director owned 111,459 shares in the company, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director owned 31,600 shares in the company, valued at $2,747,936. This represents a 5.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Trading Up 0.4%

Shares of Arrowhead Pharmaceuticals stock opened at $82.74 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $22.73 and a 12-month high of $95.49. The company has a market capitalization of $11.65 billion, a price-to-earnings ratio of -36.77 and a beta of 1.28. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The firm's 50-day moving average price is $83.71 and its two-hundred day moving average price is $73.91.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same period in the prior year, the business posted ($1.26) EPS. The company's revenue for the quarter was up 171.0% compared to the same quarter last year. On average, analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. B. Riley Financial lifted their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a "buy" rating and a $98.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. Royal Bank Of Canada reiterated an "outperform" rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday. Finally, Morgan Stanley lifted their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.42.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source